Status:
COMPLETED
Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy
Lead Sponsor:
Centre Oscar Lambret
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The scope of the trial is to identify proteomic signatures correlated with tumor response to neo-adjuvant chemotherapy.
Eligibility Criteria
Inclusion
- Women aged more than 18 years
- Histologically proven breast carcinoma
- Neo-adjuvant chemotherapy with anthracyclines and/or taxanes
- No prior chemotherapy
- Written informed consent
Exclusion
- Metastatic disease
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT00911911
Start Date
January 1 2007
End Date
July 1 2009
Last Update
July 31 2012
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Intercommunal Hospital
Annemasse, France, 74 107
2
Centre Oscar Lambret
Lille, France, 59020
3
Hopital Saint Vincent
Lille, France, 59020
4
Centre Henri Becquerel
Rouen, France, 76038